Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Biliary Tract Cancer Market Size Changed, over the years?

In recent times, there has been a robust increase in the market size of biliary tract cancer. It is projected to escalate from $0.67 billion in 2024 to an estimated $0.72 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The substantial growth seen in the past can be ascribed to the rising cases of biliary tract cancer, an augmenting demand for potent therapies, an increase in risk factors such as obesity, a growing aging population, and heightened investment in research and development.

How Much Will the Biliary Tract Cancer Market Be Worth in 2029?

There is projected robust expansion in the biliary tract cancer market in the coming years, anticipated to reach $0.95 billion by 2029, with a compound annual growth rate (CAGR) of 7.3%. The surge during the forecast period can be credited to alterations in lifestyles, increased alertness, initiatives for early detection, advantageous payback policies, and expanding governmental policies. Predominant trends for the forecast period incorporate advancements in technology for diagnosis and treatment, the acceptance of immunotherapy, a rise in the demand for precision medicine, advances in therapy approaches, and progression in therapies based on biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21114&type=smp

Which is the Largest Company in the Biliary Tract Cancer Market?

Major companies operating in the biliary tract cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Eli Lily and Company, Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Servier Pharmaceuticals, Jazz Pharmaceuticals plc, Incyte Corporation, BeiGene LTD., Zymeworks, Basilea Pharmaceutica Ltd., Taiho Oncology Inc., RenovoRx Inc., TransThera Sciences Inc., QED Therapeutics Inc., Helsinn Group

What Are the Main Market Drivers in the Biliary Tract Cancer Industry?

The biliary tract cancer market is projected to expand due to the rising occurrence of obesity. Obesity, a long-term health issue, is described by an excess build-up of body fat that can negatively impact health. The surge in obesity rates can be attributed to a lack of physical activity, psychological influences, age, and inherent biological and genetic factors. Obesity can catalyze chronic inflammation, insulin insensitivity, and an overproduction of bile acids, which results in DNA damage and tumor development. It can also upset hormones and metabolism, contributing to a biliary tract that is susceptible to cancer. For example, the Centers for Disease Control and Prevention, a government agency based in the US, revealed in September 2023 that the number of states with 35% or more adults suffering from obesity increased to 22 in 2022, from 19 in 2021. Hence, the escalating occurrence of obesity is stimulating the growth of the biliary tract cancer market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21114&type=smp

How Is the Biliary Tract Cancer Market Segments Structured?

The biliary tract cancer market covered in this report is segmented –

1) By Cancer Type: Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer

2) By Treatment: Chemotherapy, Targeted Therapy, Immunotherapy

3) By End-User: Hospitals, Specialty Cancer Centres, Ambulatory Surgical Centres, Other End-Users

Subsegments:

1) By Intrahepatic Bile Duct Cancer: Peripheral Intrahepatic Bile Duct Cancer, Hilar Intrahepatic Bile Duct Cancer

2) By Extrahepatic Bile Duct Cancer: Perihilar Bile Duct Cancer, Distal Bile Duct Cancer

3) By Gallbladder Cancer: Localized Gallbladder Cancer, Advanced Gallbladder Cancer

What Strategic Trends Are Transforming the Biliary Tract Cancer Market?

Leading firms in the biliary tract cancer market are working towards devising superior combination treatments to boost effectiveness and better patient results. Combination therapy essentially involves the simultaneous deployment of two or more medications or treatment methods to manage a single disease. For example, in November 2023, Merck & Co. Inc., a pharmaceutical firm based in the US, secured the U.S. Food and Drug Administration (FDA) approval for a combination of KEYTRUDA (pembrolizumab) with gemcitabine and cisplatin for treating patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). This key decision was motivated by the findings from the Phase 3 KEYNOTE-966 trial, which revealed a significant augmentation in overall survival, diminishing the death risk by 17% relative to chemotherapy alone. The median overall survival for patients receiving the combination therapy was concluded to be 12.7 months as compared to 10.9 months for those only subjected to chemotherapy, symbolizing this as a remarkable progression in the treatment alternatives for this intricate cancer variety.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biliary-tract-cancer-global-market-report

Which Global Regions Offer the Highest Growth in the Biliary Tract Cancer Market?

North America was the largest region in the biliary tract cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biliary tract cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21114

This Report Delivers Insight On:

1. How big is the biliary tract cancer market, and how is it changing globally?

2. Who are the major companies in the biliary tract cancer market, and how are they performing?

3. What are the key opportunities and risks in the biliary tract cancer market right now?

4. Which products or customer segments are growing the most in the biliary tract cancer market?

5. What factors are helping or slowing down the growth of the biliary tract cancer market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model